{"filing":{"accession_number":"0001193125-26-389402","cik":"0001506184","ticker":"PRRUF","company_name":"IMMUTEP Ltd","form":"6-K","filing_date":"2026-09-11","report_date":"2026-09-11","primary_document":"d127093d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1506184/000119312526389402/d127093d6k.htm"},"events":[{"id":33025,"run_id":30356,"accession_number":"0001193125-26-389402","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release discloses a material strategic pivot in Immutep's clinical development program for eftilagimod alfa following the discontinuation of the TACTI-004 trial. The company has identified manufacturing-related root causes (subtle analytical differences in N-glycan structure between 200L and 2,000L scale production), contracted a new manufacturing run, and refocused registration-directed development on HNSCC (CPS \u003c 1) and neoadjuvant STS—a significant operational and strategic decision affecting the company's development pathway and timeline (study start targeted 2H 2027). While this involves clinical/regulatory elements, the core disclosure is an operational restructuring of the development strategy and manufacturing approach, not a discrete event fitting financial, governance, or terminal categories.","company_name":"IMMUTEP Ltd","ticker":"PRRUF","filing_date":"2026-09-11","form":"6-K","submitted_at":null,"items":[{"id":36351,"accession_number":"0001193125-26-389402","item_number":"EX-99.1","item_title":"d127093dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses a material strategic pivot in Immutep's clinical development program for eftilagimod alfa following the discontinuation of the TACTI-004 trial. The company has identified manufacturing-related root causes (subtle analytical differences in N-glycan structure between 200L and 2,000L scale production), contracted a new manufacturing run, and refocused registration-directed development on HNSCC (CPS \u003c 1) and neoadjuvant STS—a significant operational and strategic decision affecting the company's development pathway and timeline (study start targeted 2H 2027). While this involves clinical/regulatory elements, the core disclosure is an operational restructuring of the development strategy and manufacturing approach, not a discrete event fitting financial, governance, or terminal categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T21:16:45.251314+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36351,"accession_number":"0001193125-26-389402","item_number":"EX-99.1","item_title":"d127093dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release discloses a material strategic pivot in Immutep's clinical development program for eftilagimod alfa following the discontinuation of the TACTI-004 trial. The company has identified manufacturing-related root causes (subtle analytical differences in N-glycan structure between 200L and 2,000L scale production), contracted a new manufacturing run, and refocused registration-directed development on HNSCC (CPS \u003c 1) and neoadjuvant STS—a significant operational and strategic decision affecting the company's development pathway and timeline (study start targeted 2H 2027). While this involves clinical/regulatory elements, the core disclosure is an operational restructuring of the development strategy and manufacturing approach, not a discrete event fitting financial, governance, or terminal categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T21:16:45.251314+00:00","company_name":"IMMUTEP Ltd","ticker":"PRRUF","filing_date":"2026-09-11"}]}